Tofersen and other antisense oligonucleotides in ALS
The advent of antisense oligonucleotide (ASO) therapies in neurodegenerative disorders is associated with enormous hope. Nusinersen treatment was a breakthrough intervention in the recessive disease spinal muscular atrophy, and superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) seems...
Saved in:
Main Authors: | Albert Ludolph, Maximilian Wiesenfarth |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/17562864251313915 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01) -
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease
by: Kaili Ou, et al.
Published: (2025-01-01) -
Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
by: Inna Shomer, et al.
Published: (2025-03-01) -
Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference
by: Olga Golounina, et al.
Published: (2025-01-01) -
Effects of Antisense Oligonucleotides against C-Reactive Protein on the Development of Atherosclerosis in WHHL Rabbits
by: Qi Yu, et al.
Published: (2014-01-01)